• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Tandem Diabetes launches t:connect healthcare portal

April 11, 2017 By Sarah Faulkner

Tandem Diabetes launches t:connect healthcare portalTandem Diabetes Care (NSDQ:TNDM) launched the t:connect HCP Portal for its cloud-based t:connect diabetes management app, which integrates with the company’s touchscreen insulin pumps.

Healthcare providers can now upload data from a Tandem pump and blood glucose meter simultaneously, according to Tandem. They can also find patients quickly and set patient-specific ranges to identify data that fall outside of goals.

The original t:connect app was designed with patient-input, Tandem said, and enables patients to monitor diabetes goals in-between clinic visits. The company reported that more than half of Tandem pump users have logged into the t:connect app in the last 90 days and upload 3 times per month on average.

The t:connect HCP Portal was developed on feedback from physicians, nurses and diabetes educators to streamline their use of the original t:connect app.

In March, Tandem announced the pricing details of a $22.5 million underwritten public offering. The company priced 18 million shares of its common stock at $1.25 apiece.

Tandem also gave underwriters a 30-day option to buy up to an additional 2.7 million shares of common stock at the public offering price. The offering is expected to close on March 28.

Earlier that month, the medical device maker met expectations on Wall Street with its 4th quarter results.

The San Diego-based company posted losses of -$15.7 million, or -48¢ per share, on sales of $24.8 million for the 3 months ended Dec. 31, for bottom-line loss of -40% on sales loss of -15% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were -48¢, ahead of consensus on The Street, where analysts were looking for sales of $22.8 million.

Filed Under: Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: Tandem Diabetes Care

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS